UA47941A - Способ лечения рака яичников 3-4 стадии - Google Patents
Способ лечения рака яичников 3-4 стадии Download PDFInfo
- Publication number
- UA47941A UA47941A UA2001117915A UA2001117915A UA47941A UA 47941 A UA47941 A UA 47941A UA 2001117915 A UA2001117915 A UA 2001117915A UA 2001117915 A UA2001117915 A UA 2001117915A UA 47941 A UA47941 A UA 47941A
- Authority
- UA
- Ukraine
- Prior art keywords
- chemotherapy
- ovarian cancer
- stage
- courses
- laferon
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 12
- 206010070907 Ovarian cancer stage III Diseases 0.000 title abstract 2
- 238000002512 chemotherapy Methods 0.000 claims abstract description 23
- 108010047126 interferon-alpha 8 Proteins 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 description 6
- 210000002747 omentum Anatomy 0.000 description 6
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000011462 intraperitoneal chemotherapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ лечения больных раком яичников 3-4 стадии включает в себя химиотерапию препаратами на основе платины в стандартных дозах. Если опухоль является высоко или умеренно дифференцированной между курсами химиотерапии назначают подкожное введение лаферона в дозе 3 миллиона единиц через день, №10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2001117915A UA47941A (ru) | 2001-11-20 | 2001-11-20 | Способ лечения рака яичников 3-4 стадии |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2001117915A UA47941A (ru) | 2001-11-20 | 2001-11-20 | Способ лечения рака яичников 3-4 стадии |
Publications (1)
Publication Number | Publication Date |
---|---|
UA47941A true UA47941A (ru) | 2002-07-15 |
Family
ID=74211937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2001117915A UA47941A (ru) | 2001-11-20 | 2001-11-20 | Способ лечения рака яичников 3-4 стадии |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA47941A (ru) |
-
2001
- 2001-11-20 UA UA2001117915A patent/UA47941A/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Milacic et al. | The tumor proteasome as a novel target for gold (III) complexes: implications for breast cancer therapy | |
RU2571551C1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
ES2575518T3 (es) | Tratamiento mejorado de mieloma múltiple | |
Luk et al. | The interaction of radiation and cis-diamminedichloroplatinum (II) in intestinal crypt cells | |
RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
JP2020523359A5 (ru) | ||
DK1750716T3 (da) | Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin | |
Bleday et al. | Inhibition of rat colon tumor isograft growth with dequalinium chloride | |
Griswold Jr et al. | Response of drug-sensitive and-resistant L1210 leukemias to high-dose chemotherapy | |
UA47941A (ru) | Способ лечения рака яичников 3-4 стадии | |
Hansen | Systemic therapy in metastatic colorectal cancer | |
BRPI0411010A (pt) | métodos para manter ou aumentar o número de glóbulos brancos do sangue em um paciente com cáncer submetido a tratamento quimioterapêutico para cáncer, para manter ou aumentar o número de plaquetas no sangue em um paciente com cáncer submetido a tratamento quimioterapêutico para cáncer e para reduzir a toxicidade gastrintestinal em um paciente com cáncer resultante de um agente quimioterapêutico anti-cáncer, composição farmacêutica, e, kit | |
CN104146999A (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 | |
CN111494385A (zh) | 一种治疗卵巢癌的药物及其制备方法和用途 | |
CN106279399A (zh) | 趋化素修饰胜肽 | |
RU2006122136A (ru) | Способ комбинированного лечения местно-распространенных форм рака шейки матки | |
CN106668061A (zh) | 一种含有顺铂的抗癌药物组合物 | |
Iosub et al. | Combination of Interferon-α and Standard Chemotherapy in Advanced Malignancies | |
RU2273502C1 (ru) | Способ лечения рецидивов рака яичников | |
RU2291497C1 (ru) | Способ лечения рака молочной железы в эксперименте | |
UA63666A (en) | Method for treating primary squamous cell cancer of anal region | |
UA58164A (ru) | Способ лечения рецидивов плоскоклеточного рака анальной области | |
RU2296564C2 (ru) | Способ лечения рецидивов у онкогинекологических больных | |
Greenberg et al. | Combination chemotherapy of Hodgkin's disease in private practice | |
NISHIHIRA et al. | Which postoperative combined therapy results in the best prognosis: radiochemocytokine therapy or aggressive chemotherapy? |